Evidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 50
- Neutral
- ConsistencyScore™
- unclear
- Not enough independent studies
Estudios de apoyo: Basado en 1 estudio
Add to Evidence TrackerResumen de Investigación
Analyzed using Evidence Intelligence™
POLYCHEM shows no superiority over standard care for diabetes remission
Última actualización 12 de septiembre de 2026
Key finding
After 16 weeks, 54 (90.0%) patients in the POLYCHEM arm achieved regression of diabetic hyperglycemia compared to 37 (77.1%) in the SDC arm (p = 0.002).
This study compared a four-drug regimen (POLYCHEM) to standard diabetes care (SDC) in newly diagnosed type 2 diabetes patients, finding no significant difference in diabetes remission but a notable improvement in hyperglycemia regression with POLYCHEM.
Quick read
Study at a glance
The essential study design details in one scan.
EvidenceScore™
Moderate
Study type
RCTs
Follow-up
Medium-Term (3–12 mo)
Risk of bias
High Risk
Guarda investigacion, organiza estudios y vuelve a encontrar evidencia importante rapidamente.
Plain-language summary
What this paper says
A plain-language read of the study’s main message and where it applies.
Study focus
This study compared a four-drug regimen (POLYCHEM) to standard diabetes care (SDC) in newly diagnosed type 2 diabetes patients, finding no significant difference in diabetes remission but a notable improvement in hyperglycemia regression with POLYCHEM.
Clinical relevance
These findings suggest that while both treatment options can lead to remission, POLYCHEM may offer additional benefits in managing hyperglycemia, which is crucial for long-term diabetes control. This could influence treatment choices for newly diagnosed patients.
Keep in mind
The study may have limited generalizability due to the specific population enrolled. Effectiveness measures were not uniformly clear across all outcomes. Sample sizes for some outcomes were relatively small.
Published in
Referencia de la Revista
Publication details and source links for this paper.
Alessandra DC, Raffaella A, Giuseppe M, et al. A four-drug regimen (POLYCHEM) vs. standard diabetes care (SDC) in newly diagnosed type 2 diabetes. Journal of Endocrinological Investigation. 2026;49(9):2521-2531. doi:10.1007/s40618-026-02930-3
Efectos Principales
At visit 3, 23 (38.3%) patients in the POLYCHEM arm achieved diabetes remission compared to 21 (43.8%) in the SDC arm (p = 0.59).
After 16 weeks, 54 (90.0%) patients in the POLYCHEM arm achieved regression of diabetic hyperglycemia compared to 37 (77.1%) in the SDC arm (p = 0.002).
Evidence network
How this study fits
Understand where this research contributes within the broader evidence network.
Evidence Context
This study contributes evidence to POLYCHEM, Standard face-to-face care and Diabetes remission, Odds ratio for response in glycated hemoglobin screening.
This study contributes evidence to
Primary intervention
POLYCHEM
Primary outcomes
- Diabetes remission
- Odds ratio for response in glycated hemoglobin screening
Evidence topics
Primary intervention
Evidence relationships
Intervention and outcome relationships this study adds to the evidence network.
4
Evidence pairs
4
Relationships
1
Evidence topics
contributes_evidence
Editorial context
Why this study matters
See why this paper is useful beyond its individual results.
Evidence network role
This section describes how the study fits into the current evidence network. It does not determine whether an intervention works on its own.
Moderate contributionModerate confidenceNetwork score: 63
1
Related topics
4
Evidence pairs
21
Related studies
High relevance in at least one topic
Why it is useful
- Contributes to 4 evidence relationships
- Includes primary outcome data
- Linked to 1 direct semantic evidence topic
Topic contributions
Evidence topic
Contributes evidence
Agrega evidencia relacionada a tu Evidence Tracker
Guarda estudios y paginas de evidencia, organiza tu Evidence Tracker y manten en un solo lugar la investigacion que te importa.
Evidencia principal
Tema de evidencia
Diabetes Remission
matched_outcome
Core evidence
Study findings
The primary outcomes reported in this study.
Odds ratio for response in glycated hemoglobin screening
POLYCHEM → Odds ratio for response in glycated hemoglobin screening
POLYCHEM → Odds ratio for response in glycated hemoglobin screening
Evidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 25
- Negative
- ConsistencyScore™
- unclear
- Not enough independent studies
Estudios de apoyo: Basado en 1 estudio
Add to Evidence TrackerDiabetes remission
Standard face-to-face care → Diabetes remission
Standard face-to-face care → Diabetes remission
Evidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 50
- Neutral
- ConsistencyScore™
- unclear
- Not enough independent studies
Estudios de apoyo: Basado en 1 estudio
Add to Evidence TrackerOdds ratio for response in glycated hemoglobin screening
Standard face-to-face care → Odds ratio for response in glycated hemoglobin screening
Standard face-to-face care → Odds ratio for response in glycated hemoglobin screening
Evidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 25
- Negative
- ConsistencyScore™
- unclear
- Not enough independent studies
Estudios de apoyo: Basado en 1 estudio
Add to Evidence TrackerEvidence Library
Build your evidence library
Save research, organize studies, and quickly find important evidence again.
La Evidencia Sugiere
- POLYCHEM led to 90% regression of hyperglycemia compared to 77.1% with SDC (p = 0.002).
- Remission rates were similar: 38.3% for POLYCHEM vs. 43.8% for SDC (p = 0.59).
A quién se aplica
- Adults newly diagnosed with type 2 diabetes.
- Patients seeking alternative treatment options for diabetes management.
Tener en Cuenta
- Results may not apply to populations outside the study's demographic.
- Further research is needed to confirm long-term benefits of POLYCHEM.
- The statistical significance of remission rates was not achieved.
Entre Líneas
- The study may have limited generalizability due to the specific population enrolled.
- Effectiveness measures were not uniformly clear across all outcomes.
- Sample sizes for some outcomes were relatively small.
Evidence Library
Build your evidence library
Save research, organize studies, and quickly find important evidence again.
Connected Evidence
Explore related studies, evidence collections, and research questions.
Relationships organized using the Dediabetes Evidence Intelligence™ framework.
This study contributes to evidence on POLYCHEM and Diabetes Remission, POLYCHEM and Odds ratio for response in glycated hemoglobin screening.
Relaciones de evidencia relacionadas
Explore in Evidence ExplorerThis study contributes to the evidence on the following intervention-outcome relationships.
Medications
POLYCHEM → Diabetes Remission
Medications
Evidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 50
- Neutral
- ConsistencyScore™
- unclear
- Not enough independent studies
Estudios de apoyo: Basado en 1 estudio
View evidenceMedications
Evidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 25
- Negative
- ConsistencyScore™
- unclear
- Not enough independent studies
Estudios de apoyo: Basado en 1 estudio
View evidenceIncluido en estas colecciones de evidencia
Curated evidence collections and hubs this study is part of.
Diabetes Remission Evidence Hub
All studies measuring Diabetes Remission
1 studies
outcome_hubMeasures Diabetes Remission as a key outcome.
Odds ratio for response in glycated hemoglobin screening Evidence Hub
All studies measuring Odds ratio for response in glycated hemoglobin screening
1 studies
outcome_hubMeasures Odds ratio for response in glycated hemoglobin screening as a key outcome.
POLYCHEM Evidence Hub
All studies on POLYCHEM
1 studies
intervention_hubContributes to POLYCHEM evidence base.
Recent Diabetes Research
Latest published studies
recency_collection
Published within the last 2 years.
Explora más en Evidence Explorer
Jump to pre-filtered views in Evidence Explorer.
All studies on POLYCHEM and Diabetes remission
Intervention: POLYCHEMOutcome: Diabetes remission
1 results
All studies on POLYCHEM and Odds ratio for response in glycated hemoglobin screening
Intervention: POLYCHEMOutcome: Odds ratio for response in glycated hemoglobin screening
1 results
All studies on POLYCHEM
Intervention: POLYCHEM
1 results
All studies measuring Diabetes remission
Outcome: Diabetes remission
1 results
All studies measuring Odds ratio for response in glycated hemoglobin screening
Outcome: Odds ratio for response in glycated hemoglobin screening
1 results
Questions answered by this study
Generated from the study's connected evidence using Evidence Intelligence™.
Does POLYCHEM improve diabetes remission?
Emerging Evidence
Current evidence does not show a clear benefit of POLYCHEM for diabetes remission.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
- 1
Diabetes remission
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | neutral | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
- Only one supporting study is available.
Does Standard face-to-face care improve diabetes remission?
Emerging Evidence
Current evidence does not show a clear benefit of Standard face-to-face care for diabetes remission.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
- 1
Diabetes remission
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | neutral | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
- Only one supporting study is available.
Does POLYCHEM lower odds ratio for response in glycated hemoglobin screening?
Emerging Evidence
POLYCHEM may worsen odds ratio for response in glycated hemoglobin screening or be associated with harm.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
- 1
Odds ratio for response in glycated hemoglobin screening
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | moderate negative | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
- Only one supporting study is available.
Does Standard face-to-face care lower odds ratio for response in glycated hemoglobin screening?
Emerging Evidence
Standard face-to-face care may worsen odds ratio for response in glycated hemoglobin screening or be associated with harm.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
- 1
Odds ratio for response in glycated hemoglobin screening
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | moderate negative | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
- Only one supporting study is available.
Next steps
Continue your research
Choose a next path through related evidence topics, Evidence Explorer views, and research summaries.
Explore in Evidence Explorer
Open broader Evidence Explorer views for this relationship.
Related research
Read related research summaries.
Bariatric surgery improves type 2 diabetes remission through gut microbiota changesDietary interventions improve diabetes remission ratesGlycated Hemoglobin Screening Improves Diabetes Identification in South AsiansIntegrated data platform improves diabetes management in adults.Low-calorie diets may improve diabetes remission in Chinese adults
Sin anuncios. Sin rastreo.
Centrada en la evidencia, no en la publicidad.
Segura y privada
Tus datos siempre están protegidos.
Siempre al día
Se agregan nuevos estudios todos los días.